May 2009
Dr. Richard D. Granstein presents at the 69th annual Society of Investigative Dermatology that GPMs are effective in reducing key inflammatory mediators in a cell based that may be useful for the identification of potential new therapeutics for rosacea. Read More
March 2009
Dr. Zoe Draelos presents Signum’s GPM Technology as a new class of topical anti-inflamatories at the American Academy of Dermatology (AAD) meeting in San Francisco.
Read More
Feb 2009
Signum Biosciences and Rohto conclude licensing agreement for first Arazine™ product. It will be introduced in Japan Q4 2009. Read More
Interested in a job at Signum? Visit our job postings section for a listing of our open positions.
In collaboration with the University of Pennsylvania we are investigating the effects of GPMs on UVB-induced inflammation.
In collaboration with the University of Medicine and Dentistry of New Jersey, we are investigating the effects of PPM compounds on α-synuclein phosphorylation in mouse models of Parkinson’s Disease.